Table 5.

PFS and HR of bevacizumab and olaparib in sequential ovarian cancer patient populations

	Platinum resistant	Platinum sensitive	Upfront
Bevacizumab	AURELIA [85]	GOG 213 [10]	GOG 218 [86]
PFS	3.4 versus 6.7 months	10.4 versus 13.8 months	11.2 versus 14.1 months
HR	0.42 (0.32–0.53 P < 0.001)	0.628 (0.534–0.739 P < 0.0001)	0.908 (0.795–1.040 P = 0.16)
Olaparib	Study 42 [84]	SOLO 2 [25]	SOLO 1 [78]
PFS	6.7 months	19.1 versus 5.5 months	Not Reached versus 13.8 months
HR	NA	0.30 (0.22–0.41 P < 0.0001)	0.30 (0.23–0.41 P > 0.0001)

PFS, progression free survival; HR, hazard ratio; GOG, Gynecologic Oncology Group; NA, not applicable.